HealthQuill diabetes
Scientists can tell how fast or gracefully you are ageing from a single magnetic resonance image of your brain, according to researchers at Duke University.
Health Medical Research

Duke researchers’ tool helps know how fast you are ageing, future diseases

HQ Team July 7, 2025: Scientists can tell how fast or gracefully you are ageing from a single magnetic resonance image of your.

Read More
The World Health Organization has unveiled a '3 by 35 initiative,’ urging governments to impose a health tax of about 50% on alcohol, sugary drinks and tobacco that are fuelling a noncommunicable disease (NCD) epidemic globally.
Drugs Health Pharma

Slap 50% tax on alcohol, sugary drinks, tobacco to curb NCDs: WHO

HQ Team July 3, 2025: The World Health Organization has unveiled a ‘3 by 35 initiative,’ urging governments to impose a health tax.

Read More
Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials in people with obesity compared to a dummy drug, the company stated.
Drugs Health Pharma

Wegovy’s weight-loss efficacy improves with higher dosage

HQ Team June 21, 2025: Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials.

Read More
Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products for diabetes and other chronic diseases.
Drugs Health Pharma

Lilly, Sweden’s Camurus sign $870 million pact for incretin products

HQ Team June 4, 2025: Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products.

Read More
Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.
Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for.

Read More
More than 84% of 345 information technology workers surveyed in an Indian city suffer from non-alcoholic fatty liver disease due to sedentary lifestyles, posing a significant health challenge, according to a study.
Drugs Health Research

In Hyderabad, India, 84% of IT workers have non-alcoholic fatty liver

HQ Team April 24, 2025: More than 84% of 345 information technology workers surveyed in an Indian city suffer from non-alcoholic fatty liver.

Read More
Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to the Massachusetts-based firm.
Drugs Health Medical

Bain Capital to buy Japan’s Mitsubishi Tanabe Pharma for $3.3 billion

Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to.

Read More
Scientists have created an atlas of individual cells within the human brain region of the hypothalamus and identified new genes linked to obesity that may lead to novel therapies.
Uncategorized

New obesity, diabetic cures may emerge as scientists unveil brain atlas 

Scientists have created an atlas of individual cells within the human brain region of the hypothalamus and identified new genes linked to obesity.

Read More
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular disease in diabetic adults with chronic kidney disease.
Drugs Health Medical

Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod

Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.

Read More
GLP-1 based weight-loss drugs have some therapeutic benefits, but the risks are as high
Drugs Pharma Research

New insights on GLP-1 drugs: Benefits and risks unveiled

HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.

Read More